Elutia Inc. (NASDAQ:ELUT - Get Free Report) Director Guido Neels purchased 20,000 shares of the business's stock in a transaction that occurred on Friday, January 30th. The stock was bought at an average cost of $1.04 per share, with a total value of $20,800.00. Following the acquisition, the director owned 118,750 shares of the company's stock, valued at approximately $123,500. The trade was a 20.25% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Elutia Trading Down 2.9%
Shares of ELUT stock opened at $1.02 on Tuesday. Elutia Inc. has a twelve month low of $0.50 and a twelve month high of $3.46. The company's 50-day moving average price is $0.72 and its 200-day moving average price is $1.15. The stock has a market cap of $43.55 million, a price-to-earnings ratio of -1.11 and a beta of 0.67.
Elutia (NASDAQ:ELUT - Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.15. The firm had revenue of $3.32 million for the quarter, compared to analyst estimates of $6.65 million. As a group, equities research analysts predict that Elutia Inc. will post -1.74 EPS for the current year.
Analysts Set New Price Targets
ELUT has been the subject of several analyst reports. Weiss Ratings reiterated a "sell (e+)" rating on shares of Elutia in a research report on Wednesday, January 21st. Wall Street Zen upgraded Elutia to a "sell" rating in a report on Saturday, November 8th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Elutia presently has an average rating of "Hold" and an average target price of $7.00.
Get Our Latest Research Report on ELUT
Institutional Investors Weigh In On Elutia
A number of institutional investors have recently modified their holdings of the company. FNY Investment Advisers LLC purchased a new stake in shares of Elutia in the 4th quarter valued at $25,000. Virtu Financial LLC acquired a new position in Elutia in the 3rd quarter valued at about $26,000. XTX Topco Ltd purchased a new stake in Elutia during the second quarter worth about $28,000. Jane Street Group LLC purchased a new position in shares of Elutia in the first quarter valued at approximately $48,000. Finally, Citadel Advisors LLC purchased a new position in shares of Elutia in the third quarter valued at approximately $50,000. 74.03% of the stock is owned by institutional investors and hedge funds.
About Elutia
(
Get Free Report)
Elutia, Inc is a biopharmaceutical company focused on the development of novel nitric oxide therapies based on its proprietary polymeric nitric oxide platform. This technology is designed to enable sustained, controlled release of nitric oxide to targeted tissues, potentially overcoming the delivery challenges associated with gaseous nitric oxide and small‐molecule donors.
The company's lead program is in preclinical development for pulmonary arterial hypertension, with additional research efforts aimed at other cardiovascular and respiratory conditions.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
